The global aquaculture industry is becoming increasingly dependent on effective disease-prevention strategies as fish farming expands and production systems become more intensive. Higher stocking densities, international seafood trade, and the expansion of commercial aquaculture can increase exposure to bacterial, viral, and parasitic pathogens. Vaccination is consequently gaining importance as producers look for ways to protect fish health, reduce mortality, improve production consistency, and limit dependence on antimicrobial treatments. At the same time, biotechnology is opening new possibilities for recombinant, DNA-based, oral, and other next-generation vaccines designed for specific species and pathogens. 

Market Overview & Core Figures

According to Grand View Research, the aquaculture vaccines industry is entering a period of strong expansion as disease prevention becomes increasingly important for sustainable fish production.

• Market size, 2025: USD 230.4 million 

• Estimated market size, 2026: USD 249.0 million 

• Projected market size, 2033: USD 467.3 million 

• CAGR, 2026–2033: 9.4% 

• North America revenue share, 2025: 38.0% 

The industry's expansion is being supported by rising disease incidence, increasing government support for sustainable aquaculture, stricter biosecurity measures, and continuing technological improvements in vaccine development. Grand View Research notes that disease outbreaks account for over 30% of total aquaculture production losses in countries such as China, India, and Vietnam, while approximately 50% of global aquaculture losses are caused by disease. 

Download a free sample copy of the Aquaculture Vaccines Market report to understand detailed coverage and inclusions in the final report

Key Market Segmentation

Vaccine Type: Attenuated Live Vaccines Lead

Attenuated live vaccines represented the leading product category, accounting for 49.9% of revenue in 2025. These vaccines contain weakened pathogens that stimulate strong immune responses while maintaining an established safety profile. Their ability to provide robust and long-lasting immunity makes them particularly valuable for large-scale aquaculture operations.

They are also being used against bacterial and viral diseases such as vibriosis and furunculosis. Because vaccination can reduce disease-related mortality and minimize the need for repeated antimicrobial interventions, live attenuated products remain an important part of aquaculture health-management programs. 

The other vaccines category—including DNA, recombinant, subunit, and peptide-based products—is expected to record the fastest growth. These technologies are attracting investment because they can provide targeted immunization, improved safety, and more precise antigen expression. Research is also expanding toward complex diseases such as sea lice and viral nervous necrosis. 

Route of Administration: Injection Dominates

Injected vaccines held the largest revenue share in 2025. Injection is widely used because it provides accurate dosing and can generate strong, long-lasting immunity. The technique is particularly relevant for high-value species such as salmon and trout, where individual vaccination can be economically justified. 

Oral delivery is attractive because vaccines can be administered through feed without individually handling fish. This reduces labor requirements and injection-related stress while making mass immunization more practical, particularly for juvenile and smaller fish.

Application: Bacterial Diseases Remain the Major Target

The bacterial application segment dominated in 2025. Bacterial pathogens such as Aeromonas, Vibrio, and Edwardsiella can cause mortality, slow growth, and significant economic losses for producers.

Vaccines designed against bacterial diseases can therefore play an important role in improving farm productivity and protecting fish welfare. At the same time, the viral segment is expected to register the fastest CAGR, supported by growing concern about diseases such as Infectious Salmon Anaemia, Viral Nervous Necrosis, and Koi Herpesvirus. 

Major Growth Drivers and Trends

Intensification of Aquaculture

The continued development of high-density fish farming is increasing the importance of preventive healthcare. When fish are raised in concentrated environments, pathogens can spread rapidly and potentially affect large numbers of animals.

Vaccination provides producers with a proactive approach to disease management. Rather than responding only after an outbreak occurs, farmers can incorporate vaccination into broader health and biosecurity programs.

Reducing Dependence on Antibiotics

One of the most important structural trends is the movement toward reducing antimicrobial use in aquaculture. Vaccination can help prevent infections before they occur, reducing the need for antibiotics and supporting more sustainable production practices. Grand View Research highlights the role of fish vaccines in reducing dependence on antimicrobial agents. 

This shift is particularly relevant as regulators, seafood producers, and consumers place greater emphasis on animal welfare, environmental sustainability, and responsible food production.

Biotechnology Is Expanding Vaccine Options

Advances in biotechnology are creating new approaches to aquaculture immunization. Recombinant DNA technologies, yeast expression platforms, multivalent vaccines, and other approaches are being investigated to improve protection against complex pathogens.

The development of vaccines tailored to individual species and disease profiles can also improve the effectiveness of disease-control programs. These advances are helping diversify the industry beyond conventional vaccine technologies. 

Oral and Immersion Technologies

Non-invasive vaccination methods are attracting considerable attention because individual injection can be difficult and expensive when large numbers of fish must be treated.

Oral vaccines administered through feed offer a practical alternative, while immersion and spray approaches can potentially support mass vaccination during early stages of fish development. However, these technologies still face challenges related to dosing, antigen stability, immune response, and consistency of protection. 

Looking for more specific insights? Customize this report to suite your business needs

Regional Insights

North America – Current Market Leader

North America accounted for 38.0% of global revenue in 2025, making it the largest regional market. The U.S. held the largest country-level revenue share during the year. Strong aquaculture health infrastructure, established animal-health companies, and increasing attention to disease prevention support regional demand. 

Asia Pacific – Strong Growth Opportunity

Asia Pacific is emerging as a major opportunity as commercial aquaculture expands across China, India, Vietnam, Thailand, and other countries. Rising seafood consumption, expanding aquaculture production, disease-management requirements, and government investment are creating favorable conditions for vaccine adoption.

Governments and research institutions are also supporting domestic vaccine development. Grand View Research cites India's Marine & Aquaculture Biotechnology program as an initiative focused on improving sustainability and fish health through areas including vaccine development. 

Leading Industry Competitors

The aquaculture vaccines industry has a moderately concentrated competitive structure, with major animal-health companies competing alongside regional specialists.

Key companies include:

• Zoetis 

• Phibro Animal Health Corporation 

• Elanco 

• Merck & Co., Inc. 

• KBNP 

• CAVAC 

• Kyoto Biken Laboratories, Inc. 

• Nisseiken Co., Ltd. 

• Vaxxinova International BV 

• HIPRA 

Companies are focusing on R&D, strategic partnerships, regional distribution, and species-specific solutions. For instance, Indian Immunologicals Limited partnered with ICAR-CIBA in August 2024 to develop a recombinant vaccine for viral nervous necrosis in finfish. 

The competitive landscape is also experiencing strategic consolidation. In February 2025, MSD Animal Health acquired Elanco's aqua business, strengthening its portfolio of aquaculture vaccines, therapeutics, and related facilities.